Abstract
Objective: To investigate the possible involvement of cytochromes CYP1A2 and CYP2C19 in the in vivo oxidative metabolism of quinidine.
Methods: This was an open study of six healthy young male volunteers. The pharmacokinetics of a 200-mg single oral dose of quinidine were studied before and during daily treatment with 100 mg fluvoxamine. Biomarkers of other isozyme activities in the form of caffeine, sparteine, mephenytoin, tolbutamide and cortisol metabolism were applied.
Results: The results showed a statistically significant median reduction of 29–44% in the quinidine total apparent oral clearance, partial clearances by 3-hydroxylation and N-oxidation and residual clearance during fluvoxamine treatment. Renal clearance was unaffected by fluvoxamine.
Conclusions: The effect of fluvoxamine on the formation clearances of 3-hydroxyquinidine and quinidine-N-oxide most likely reflects inhibition of cytochrome P 4503A4 by fluvoxamine at clinically relevant doses. The results of this study do not rule out a possible involvement of CYP1A2 and CYP2C19 in the in vivo oxidative metabolism of quinidine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 16 December 1998 / Accepted in revised form: 5 March 1999
Rights and permissions
About this article
Cite this article
Damkier, P., Hansen, L. & Brøsen, K. Effect of fluvoxamine on the pharmacokinetics of quinidine. E J Clin Pharmacol 55, 451–456 (1999). https://doi.org/10.1007/s002280050655
Issue Date:
DOI: https://doi.org/10.1007/s002280050655